TheraRadar
Clinical-Stage Companies / Shanghai Haiyan Pharmaceutical Technology

Shanghai Haiyan Pharmaceutical Technology

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 4/1/2025

14
Total Trials
3
Phase 3
3
Phase 2
7
Recruiting
93
Score

Pipeline by Phase

Phase 3
3
Phase 2
3
Phase 1
8

Therapeutic Focus

Insomnia Insomnia Disorder Pain Central Nervous System Postoperative Analgesia

Clinical Trials (14)

NCT06975514 Phase 3 RECRUITING

Safety and Efficacy Study of YZJ-1139 Tablets in Insomnia Disorder

Started: 3/25/2025

NCT05525637 Phase 3 RECRUITING

Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder

Started: 12/17/2021

NCT06890533 Phase 3 NOT YET RECRUITING

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

Started: 4/1/2025

NCT06901830 Phase 2 NOT YET RECRUITING

A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery

Started: 4/1/2025

NCT06680505 Phase 2 COMPLETED

Safety and Efficacy Study of YZJ-1139 in Primary Chronic Insomnia Disorder

Started: 8/4/2019

NCT06680466 Phase 2 ACTIVE NOT RECRUITING

A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery

Started: 12/26/2023

NCT06209385 Phase 1 RECRUITING

A Phase 1 Study of YZJ-5053 Tablets in Participants With Advanced Solid Tumors

Started: 8/11/2023

NCT06673927 Phase 1 COMPLETED

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of YZJ-1139 in Healthy Participants

Started: 12/1/2017

NCT06685341 Phase 1 COMPLETED

PK/PD Study of YZJ-1139

Started: 3/7/2019

NCT06680531 Phase 1 ACTIVE NOT RECRUITING

A Clinical Study to Evaluate the Drug Interaction Between YZJ-1139 Tablets and Escitalopram Oxalate Tablets

Started: 8/31/2024

NCT06681493 Phase 1 COMPLETED

A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects

Started: 10/12/2022

NCT06671444 Phase 1 ACTIVE NOT RECRUITING

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Severe Renal Impairment and Normal Renal Impairment

Started: 6/3/2024

NCT06671470 Phase 1 ACTIVE NOT RECRUITING

A Drug-drug Interaction Study of YZJ-1139 Tablets and Ticagrelor Tablets in Healthy Subjects

Started: 8/22/2024

NCT06671509 Phase 1 COMPLETED

Pharmacokinetics and Safety Study of YZJ-1139 in Subjects With Mild, Moderate and Normal Hepatic Impairment

Started: 3/22/2024

Drug Candidates

YZJ-1139 Zolpidem YZJ-4729 Placebo Comparator: Saline Active Comparator: Morphine Experimental: YZJ-4729 Placebo YZJ-1139 10mg YZJ-1139 20mg YZJ-1139 40mg
Activity Status: Slowing
Last Trial Started: 4/1/2025
Last Trial Ended: 8/7/2024
Trials (12 months): 0
Completed Trials: 5
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.